- Delivery Method:
- Via Electronic Mail - Return Receipt Requested
- Reference #:
- FEI 3004021253
- Product:
- Drugs
- Recipient:
-
Recipient Name
Dr. Sanjay Chaturvedi
-
Recipient Title
Chief Executive Officer
- Apitoria Pharma Private Limited Unit 1
Floor No.’s 22, 23, & 24. Galaxy, Plot No-1, Survey no: 83/1
Knowledge City, Raidurg
Hyderabad 500032
Telangana
India-
- sanjay@apitoria.com
- Issuing Office:
- Center for Drug Evaluation and Research (CDER)
United States
Secondary Issuing Offices
Dear Dr. Chaturvedi:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning 320-22-10 dated January 12, 2022.
Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.
The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Daniel W. Brisker
Compliance Officer
Division of Drug Quality II
